Insider Selling: Paysign, Inc. (NASDAQ:PAYS) CEO Sells $129,600.00 in Stock

Posted by John Adams on Nov 23rd, 2024

Paysign, Inc. (NASDAQ:PAYS – Get Free Report) CEO Mark Newcomer sold 40,000 shares of Paysign stock in a transaction that occurred on Monday, November 18th. The shares were sold at an average price of $3.24, for a total value of $129,600.00. Following the completion of the transaction, the chief executive officer now owns 9,296,886 shares of the company’s stock, valued at approximately $30,121,910.64. The trade was a 0.43 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Mark Newcomer also recently made the following trade(s):

On Wednesday, November 20th, Mark Newcomer sold 25,000 shares of Paysign stock. The shares were sold at an average price of $3.27, for a total value of $81,750.00.
On Wednesday, October 23rd, Mark Newcomer sold 36,000 shares of Paysign stock. The shares were sold at an average price of $3.66, for a total value of $131,760.00.
On Monday, October 21st, Mark Newcomer sold 22,000 shares of Paysign stock. The shares were sold at an average price of $3.75, for a total value of $82,500.00.
On Monday, September 23rd, Mark Newcomer sold 50,000 shares of Paysign stock. The shares were sold at an average price of $4.25, for a total value of $212,500.00.
On Thursday, September 19th, Mark Newcomer sold 1,500 shares of Paysign stock. The shares were sold at an average price of $4.50, for a total value of $6,750.00.
On Friday, September 13th, Mark Newcomer sold 1,500 shares of Paysign stock. The stock was sold at an average price of $4.50, for a total value of $6,750.00.

Paysign Trading Up 0.6 %

Shares of NASDAQ PAYS opened at $3.46 on Friday. The stock has a 50 day simple moving average of $3.83 and a 200-day simple moving average of $4.29. The company has a market cap of $185.28 million, a PE ratio of 23.07 and a beta of 0.95. Paysign, Inc. has a 12-month low of $2.22 and a 12-month high of $5.59.

Paysign (NASDAQ:PAYS – Get Free Report) last announced its earnings results on Tuesday, November 5th. The company reported $0.03 EPS for the quarter, topping the consensus estimate of $0.01 by $0.02. Paysign had a return on equity of 30.64% and a net margin of 14.28%. The firm had revenue of $15.26 million for the quarter, compared to analysts’ expectations of $14.96 million. During the same quarter in the previous year, the company earned $0.02 earnings per share. Sell-side analysts forecast that Paysign, Inc. will post 0.21 earnings per share for the current fiscal year.

Analyst Ratings Changes

Separately, Barrington Research reiterated an “outperform” rating and set a $7.00 price objective on shares of Paysign in a research report on Monday, November 4th.

Check Out Our Latest Research Report on PAYS

Institutional Investors Weigh In On Paysign

Several hedge funds and other institutional investors have recently added to or reduced their stakes in PAYS. SG Americas Securities LLC bought a new stake in Paysign during the third quarter worth approximately $43,000. Algert Global LLC bought a new position in shares of Paysign in the second quarter valued at $46,000. The Manufacturers Life Insurance Company bought a new position in shares of Paysign in the second quarter valued at $66,000. American Century Companies Inc. bought a new position in shares of Paysign in the second quarter valued at $92,000. Finally, Bard Associates Inc. bought a new position in shares of Paysign in the third quarter valued at $103,000. Institutional investors own 25.89% of the company’s stock.

About Paysign

(Get Free Report)

Paysign, Inc provides prepaid card programs, comprehensive patient affordability offerings, digital banking services, and integrated payment processing services for businesses, consumers, and government institutions. Its product offerings include solutions for corporate rewards, prepaid gift cards, general purpose reloadable debit cards, employee incentives, consumer rebates, donor compensation, clinical trials, healthcare reimbursement payments and pharmaceutical payment assistance, and demand deposit accounts accessible with a debit card.